Bpifrance

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Multiwave Technologies develops breakthrough magnetic resonance imaging and positron emission tomography devices, including metamaterial MRI antennas designed by its French unit. The company aims to improve MRI image quality and support clinical decision making, including portable MRI capabilities and sensor-based performance analysis. Founded in 2015 in Switzerland, it is headquartered in Geneva and conducts research and development in France, reflecting an international footprint. The business is recognized for its metamaterial MRI antenna design and positions itself as a deep science imaging innovator in neurology and other medical imaging applications.

Multiwave Technologies develops breakthrough magnetic resonance imaging and positron emission tomography devices, including metamaterial MRI antennas designed by its French unit. The company aims to improve MRI image quality and support clinical decision making, including portable MRI capabilities and sensor-based performance analysis. Founded in 2015 in Switzerland, it is headquartered in Geneva and conducts research and development in France, reflecting an international footprint. The business is recognized for its metamaterial MRI antenna design and positions itself as a deep science imaging innovator in neurology and other medical imaging applications.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

The Agent is a company that transforms the digital distribution landscape for fashion brands. It operates a platform that links numerous European designer brands with e-retailers across 30 countries, including the USA, Australia, the UK, Germany, Spain, Switzerland, Sweden, Russia, and regions in Eastern Europe, the Middle East, and Africa. By facilitating these connections, The Agent enables fashion brands to reach a broader audience and enhances the online shopping experience for consumers seeking diverse designer offerings.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

Recommerce Group specializes in the trade-in, refurbishment, and remarketing of second-hand smartphones across Europe. Founded in 2009 and headquartered in Paris, France, the company employs advanced proprietary technologies to give a second life to mobile devices, offering a wide array of premium quality products under its own brand. Recommerce Group provides comprehensive solutions that include buyback services, real-time market pricing, and leasing programs, facilitating affordable access to refurbished electronics. The company serves a diverse clientele, including mobile network operators, distributors, e-tailers, and manufacturers, through both online and physical distribution channels in France, Switzerland, Spain, and beyond. Additionally, Recommerce Group offers marketing and logistical support, as well as customer services, ensuring a seamless experience for its partners and customers alike.